Experimental therapeutics for patients with myeloproliferative neoplasias

Meetu Agrawal, Ravin J. Garg, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek, Alfonso Quintas-Cardama

Research output: Contribution to journalReview article

Abstract

Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are characterized by stem cell-derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph-negative MPNs including essential thrombocythemia (ET); polycythemia vera (PV); primary myelofibrosis (PMF); mastocytosis; chronic eosinophilic leukemia; chronic neutrophilic leukemia; and MPN, unclassifiable. For many years, the treatment of ET, PV, and PMF, the most frequently diagnosed Ph-negative MPNs, has been largely supportive. In recent years, that paradigm has been challenged because of the discovery of a recurrent point mutation in the Janus kinase 2 (JAK2) gene (JAK2V617F). This mutation can be detected in the vast majority of patients with PV and approximately half of patients with ET or PMF and serves as both a diagnostic marker as well as representing a putative molecular target for drug development. Several putative targeted agents with significant in vitro JAK2 inhibitory activity and various degrees of JAK2 specificity are currently undergoing clinical evaluation. Furthermore, other investigational non-tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon-α have also shown promising results in MPNs.

Original languageEnglish (US)
Pages (from-to)662-676
Number of pages15
JournalCancer
Volume117
Issue number4
DOIs
StatePublished - Feb 15 2011
Externally publishedYes

Fingerprint

Janus Kinase 2
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Neoplasms
Leukemia, Neutrophilic, Chronic
Mastocytosis
Therapeutics
Philadelphia Chromosome
Point Mutation
Interferons
Phosphotransferases
Stem Cells
Mutation
Pharmaceutical Preparations
Genes

Keywords

  • INCB018424
  • JAK2 inhibitors
  • Janus kinase (JAK2) V617F
  • lenalidomide
  • myeloproliferative neoplasias
  • pegylated interferon

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Agrawal, M., Garg, R. J., Cortes, J., Kantarjian, H., Verstovsek, S., & Quintas-Cardama, A. (2011). Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer, 117(4), 662-676. https://doi.org/10.1002/cncr.25672

Experimental therapeutics for patients with myeloproliferative neoplasias. / Agrawal, Meetu; Garg, Ravin J.; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan; Quintas-Cardama, Alfonso.

In: Cancer, Vol. 117, No. 4, 15.02.2011, p. 662-676.

Research output: Contribution to journalReview article

Agrawal, M, Garg, RJ, Cortes, J, Kantarjian, H, Verstovsek, S & Quintas-Cardama, A 2011, 'Experimental therapeutics for patients with myeloproliferative neoplasias', Cancer, vol. 117, no. 4, pp. 662-676. https://doi.org/10.1002/cncr.25672
Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15;117(4):662-676. https://doi.org/10.1002/cncr.25672
Agrawal, Meetu ; Garg, Ravin J. ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan ; Quintas-Cardama, Alfonso. / Experimental therapeutics for patients with myeloproliferative neoplasias. In: Cancer. 2011 ; Vol. 117, No. 4. pp. 662-676.
@article{37f7909453f944b8a0a38f0665c0bb03,
title = "Experimental therapeutics for patients with myeloproliferative neoplasias",
abstract = "Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are characterized by stem cell-derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph-negative MPNs including essential thrombocythemia (ET); polycythemia vera (PV); primary myelofibrosis (PMF); mastocytosis; chronic eosinophilic leukemia; chronic neutrophilic leukemia; and MPN, unclassifiable. For many years, the treatment of ET, PV, and PMF, the most frequently diagnosed Ph-negative MPNs, has been largely supportive. In recent years, that paradigm has been challenged because of the discovery of a recurrent point mutation in the Janus kinase 2 (JAK2) gene (JAK2V617F). This mutation can be detected in the vast majority of patients with PV and approximately half of patients with ET or PMF and serves as both a diagnostic marker as well as representing a putative molecular target for drug development. Several putative targeted agents with significant in vitro JAK2 inhibitory activity and various degrees of JAK2 specificity are currently undergoing clinical evaluation. Furthermore, other investigational non-tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon-α have also shown promising results in MPNs.",
keywords = "INCB018424, JAK2 inhibitors, Janus kinase (JAK2) V617F, lenalidomide, myeloproliferative neoplasias, pegylated interferon",
author = "Meetu Agrawal and Garg, {Ravin J.} and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek and Alfonso Quintas-Cardama",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/cncr.25672",
language = "English (US)",
volume = "117",
pages = "662--676",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Experimental therapeutics for patients with myeloproliferative neoplasias

AU - Agrawal, Meetu

AU - Garg, Ravin J.

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

AU - Quintas-Cardama, Alfonso

PY - 2011/2/15

Y1 - 2011/2/15

N2 - Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are characterized by stem cell-derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph-negative MPNs including essential thrombocythemia (ET); polycythemia vera (PV); primary myelofibrosis (PMF); mastocytosis; chronic eosinophilic leukemia; chronic neutrophilic leukemia; and MPN, unclassifiable. For many years, the treatment of ET, PV, and PMF, the most frequently diagnosed Ph-negative MPNs, has been largely supportive. In recent years, that paradigm has been challenged because of the discovery of a recurrent point mutation in the Janus kinase 2 (JAK2) gene (JAK2V617F). This mutation can be detected in the vast majority of patients with PV and approximately half of patients with ET or PMF and serves as both a diagnostic marker as well as representing a putative molecular target for drug development. Several putative targeted agents with significant in vitro JAK2 inhibitory activity and various degrees of JAK2 specificity are currently undergoing clinical evaluation. Furthermore, other investigational non-tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon-α have also shown promising results in MPNs.

AB - Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) are characterized by stem cell-derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph-negative MPNs including essential thrombocythemia (ET); polycythemia vera (PV); primary myelofibrosis (PMF); mastocytosis; chronic eosinophilic leukemia; chronic neutrophilic leukemia; and MPN, unclassifiable. For many years, the treatment of ET, PV, and PMF, the most frequently diagnosed Ph-negative MPNs, has been largely supportive. In recent years, that paradigm has been challenged because of the discovery of a recurrent point mutation in the Janus kinase 2 (JAK2) gene (JAK2V617F). This mutation can be detected in the vast majority of patients with PV and approximately half of patients with ET or PMF and serves as both a diagnostic marker as well as representing a putative molecular target for drug development. Several putative targeted agents with significant in vitro JAK2 inhibitory activity and various degrees of JAK2 specificity are currently undergoing clinical evaluation. Furthermore, other investigational non-tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon-α have also shown promising results in MPNs.

KW - INCB018424

KW - JAK2 inhibitors

KW - Janus kinase (JAK2) V617F

KW - lenalidomide

KW - myeloproliferative neoplasias

KW - pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=79551718200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551718200&partnerID=8YFLogxK

U2 - 10.1002/cncr.25672

DO - 10.1002/cncr.25672

M3 - Review article

C2 - 20922795

AN - SCOPUS:79551718200

VL - 117

SP - 662

EP - 676

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -